Sarepta Therapeutics Sees Unusually High Options Volume (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) saw some unusual options trading activity on Wednesday. Traders bought 4,867 call options on the company. This is an increase of approximately 60% compared to the typical volume of 3,049 call options.

Hedge Funds Weigh In On Sarepta Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Kestra Advisory Services LLC purchased a new position in Sarepta Therapeutics in the 4th quarter worth approximately $25,000. iSAM Funds UK Ltd purchased a new position in Sarepta Therapeutics in the 3rd quarter worth approximately $25,000. Ancora Advisors LLC boosted its holdings in Sarepta Therapeutics by 200.0% in the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 1,000 shares during the period. Allworth Financial LP boosted its holdings in Sarepta Therapeutics by 2,098.8% in the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 1,721 shares during the period. Finally, Larson Financial Group LLC boosted its holdings in Sarepta Therapeutics by 82.5% in the 4th quarter. Larson Financial Group LLC now owns 1,882 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 851 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on SRPT. Wall Street Zen raised shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Oppenheimer reaffirmed an “outperform” rating and set a $37.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, March 19th. Mizuho upped their price objective on shares of Sarepta Therapeutics from $26.00 to $31.00 and gave the company an “outperform” rating in a research note on Thursday, March 12th. Royal Bank Of Canada upped their price objective on shares of Sarepta Therapeutics from $18.00 to $19.00 and gave the company a “sector perform” rating in a research note on Tuesday, April 7th. Finally, Citigroup upped their price objective on shares of Sarepta Therapeutics from $9.00 to $13.00 and gave the company a “sell” rating in a research note on Thursday, March 26th. Eight investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and six have issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $24.77.

Sarepta Therapeutics Trading Up 11.7%

SRPT traded up $1.84 on Wednesday, reaching $17.62. 1,292,077 shares of the company’s stock were exchanged, compared to its average volume of 2,894,667. The company’s 50 day moving average is $18.93 and its 200-day moving average is $19.69. The company has a market cap of $1.86 billion, a price-to-earnings ratio of -18.11, a PEG ratio of 0.17 and a beta of 0.21. Sarepta Therapeutics has a twelve month low of $10.41 and a twelve month high of $25.32. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.62 and a current ratio of 4.63.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $2.18. The firm had revenue of $730.80 million during the quarter, compared to the consensus estimate of $474.16 million. Sarepta Therapeutics had a negative net margin of 2.94% and a positive return on equity of 7.56%. The company’s revenue was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($3.42) EPS. Equities analysts predict that Sarepta Therapeutics will post 3.99 earnings per share for the current year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.